Nvidia among investors in xAI’s $20 bln capital raise- Bloomberg
LONDON - ImmuPharma PLC (LSE:IMM) has filed a new patent application for its lead compound P140, which the company describes as an "Immunormalizer" for diagnosing and treating autoimmune diseases, according to a press release statement issued Monday.
The patent application could provide 20 years of commercial exclusivity for a diagnostic test and treatment approach that identifies patients with what the company terms "Type M immune disorder" who may respond better to P140 therapy.
The company states the approach could potentially be used to treat up to 50 different autoimmune diseases. The diagnostic test aims to identify suitable patients and monitor treatment response.
According to the release, P140 works by restoring immune homeostasis rather than suppressing the immune system like conventional treatments. The company claims this approach may avoid infection and cancer risks associated with existing therapies.
ImmuPharma CEO Tim McCarthy called the patent filing "a game changer" that "greatly expands the scope of P140 across a wide range of autoimmune diseases."
The company indicates the diagnostic component could shorten diagnosis time for patients and improve clinical trial design by enabling better patient selection.
Autoimmune diseases affect more than 400 million people worldwide, with a therapeutic market valued at over $100 billion annually, according to the company’s statement.
The research behind the patent application was led by Dr. Sébastien Goudreau and Dr. Laura Mauran-Ambrosino at ImmuPharma Biotech, the company’s research division.
ImmuPharma is a specialty biopharmaceutical company focused on developing peptide-based therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.